<DOC>
	<DOCNO>NCT02526784</DOCNO>
	<brief_summary>The purpose trial compare severity ISRs ( Injection Site Reactions ) follow degarelix subcutaneous ( s.c. ) administration two different injection technique intramuscular ( i.m . ) administration patient hormone dependent prostate cancer .</brief_summary>
	<brief_title>A Trial Evaluating Two Subcutaneous Injection Techniques Intramuscular Administration Degarelix Patients With Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Aged â‰¥18 year diagnosis adenocarcinoma prostate ( Gleason grade , stage ) endocrine treatment indicate . Caucasian origin . Able provide write Informed Consent willing able comply trial procedure . Body mass index ( BMI ) 18.530 kg/m2 . Has life expectancy least one year . Current hormonal management prostate cancer . Previous endocrine therapy prostate cancer within 3 month prior screen visit . Any medical injection therapy might interfere degarelix injection . Patients advanced muscle atrophy cachexia Investigator 's opinion would preclude pose risk complication follow ventrogluteal i.m . injection degarelix . Any medical condition could aggravate may cause extreme discomfort trial period could cause moderate risk patient ( significant heart , renal liver disease ) . Chronic pain syndrome continuous pain report patient , accord judgement Investigator , could limit evaluation injection relate pain .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>